Introduction and objective: Ocrelizumab is used in multiple sclerosis treatment and is available in intravenous and subcutaneous forms. In Poland, only the intravenous form is currently reimbursed. The subcutaneous form offers a shorter administration time, potentially benefiting both healthcare providers and patients. This study evaluates the impact of the different forms of ocrelizumab administration on medical facility workflow and costs. Materials and methods: A survey was conducted in six medical centres involving 329 patients treated with ocrelizumab in 2023, with 46 patients receiving the subcutaneous form of the drug. The study assessed the complete drug administration process, including premedication, preparation, administration, and post-administration observation. The comparison between the two forms of ocrelizumab focused on the costs associated with drug administration, the time patients spent at the medical centre, and the efficiency of the drug administration process. Results: The administration costs of the subcutaneous form were significantly lower (96.80 PLN) than the intravenous form (224.32 PLN). The time patients spent at the medical centre was greatly reduced for the subcutaneous form (56 minutes) compared to the intravenous form (242 minutes). Efficiency in drug administration was also higher for the subcutaneous (26.88) than the intravenous form (2.62). Conclusions: The study highlights the substantial benefits of the subcutaneous form of ocrelizumab over the intravenous form. These advantages are noticeable from both the healthcare provider’s and patient’s perspectives, underscoring the potential for improved efficiency and patient experience with the subcutaneous form.